We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Global POC Urinalysis Market Driven by Nephropathic Disorders and UTIs

By LabMedica International staff writers
Posted on 18 Dec 2018
The global point of care (POC) urinalysis market is projected to grow at a CAGR of more than 3% over the 2018-2022 period, driven mainly by the rising prevalence of nephropathic disorders and urinary tract infections (UTIs) which is generating higher demand for various types of urine tests. More...
These are the latest findings of Technavio Research, (London, UK), a global technology research and advisory company.

Lifestyle diseases such as obesity, diabetes, and hypertension adversely impact the excretion system, including the lungs, kidneys, skin, bladder, and urinary tract. This impacts the appearance, concentration, and content of urine, resulting in various nephropathic disorders. Globally, UTI is the most common non-intestinal infection, whereas chronic kidney disease (CKD) is a major public health problem. The increase in the incidence of UTIs and nephropathic disorders is driving the growing demand for diagnostic systems, especially POC, as it is the fastest growing segment of the diagnostic systems market. A urinary screening program is recommended as a fundamental element for reducing the incidence of CKDs and UTIs, which is expected to fuel the demand for urinalysis tests and boost the growth of the POC urinalysis market.

The global POC urinalysis market is expected to become slightly fragmented during the forecast period due to the presence of several POC urinalysis device manufacturers who are offering POC devices, such as urinalysis test systems and urinalysis test consumables. The growth of the global POC urinalysis market is likely to be further supported by emerging technologies in POC testing. A number of POC urinalysis device manufacturers are focusing on developing new technologies, such as lateral flow immunoassay (LFIA) platforms, reflectometry, and automated urine microscopy analyzers.

Various companies are developing and distributing products in partnership, which helps them to cover a larger geographical area and earn higher return on earnings (ROI) as the products are co-developed and marketed. Such combined products provide better analysis by continuous load-and-go processing with no centrifugation, reduced offline dilutions, and fewer manual steps. With several established POC urinalysis device manufacturers battling for market share, the players will need to differentiate themselves in order to gain significant traction over their peers.

Geographically, in 2017, the largest share in the global POC urinalysis market was held by the Americas at 45%, followed by EMEA (Europe, the Middle East and Africa) and APAC (Asia Pacific). The Americas is expected to continue dominating the global POC urinalysis market during the forecast period with a share of almost 43%, led by the high prevalence of CKD and UTIs in the region, as well as increasing health consciousness of lifestyle diseases among its population. On the other hand, the POC urinalysis market in APAC is projected to register the fastest growth among the three regions.

Related Links:
Technavio Research


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Genomic Tissue Test Predicts Metastasis and Abiraterone Benefit in High-Risk Prostate Cancer

Prostate cancer is the most common cancer in men, affecting more than 1 million men worldwide in 2013. Its clinical course varies substantially between patients, complicating efforts to identify those... Read more

Hematology

view channel
Image: Acute lymphoblastic leukemia in children and young people requires careful relapse risk assessment as treatment expands beyond standard chemotherapy. (Image Credit: Shutterstock)

New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL

Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea

Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read more

Pathology

view channel
Image: The CE-marked software IVD combines digital histopathology and clinicopathological data to generate a prognostic classification (Image Credit: Shutterstock)

Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer

In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. However, individual risks... Read more

Technology

view channel
Image: Diatech Pharmacogenetics launches Labcycler, a compact PCR thermal cycler. (Photo courtesy of Diatech Pharmacogenetics)

Compact PCR Thermal Cycler Launches for Routine Molecular Laboratory Workflows

Molecular laboratories rely on nucleic acid analysis to detect molecular information accurately and reproducibly across a wide range of applications. Supporting these routine workflows, a newly launched... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.